Stockscreener 앱 받기
4.50
1.13%
0.07
전일 마감가:
$4.43
열려 있는:
$4.45
하루 거래량:
461.29K
Relative Volume:
0.16
시가총액:
$56.95M
수익:
-
순이익/손실:
$-30.54M
주가수익비율:
-2.9032
EPS:
-1.55
순현금흐름:
$-18.30M
1주 성능:
-8.20%
1개월 성능:
-29.34%
6개월 성능:
+585.33%
1년 성능:
+1,020%
1일 변동 폭
$4.38
$4.64
1주일 범위
$4.38
$4.96
52주 변동 폭
$0.202
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
명칭
Unicycive Therapeutics Inc
전화
650-384-0642
주소
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
UNCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.505 | 62.31M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.08 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.13 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.49 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.22 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.77 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | Guggenheim | Buy |
| 2024-04-04 | 개시 | Piper Sandler | Overweight |
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Unicycive Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - Autocar Professional
Best Stocks for a Post COVID Recovery in India Financial Expert RecommendationsFree Stock Market Trend Analysis - PrintWeekIndia
What analysts say about Palladyne AI Corp. stockRapid growth trajectories - jammulinksnews.com
Unicycive Therapeutics Inc. Stock Analysis and ForecastPhenomenal trading returns - Autocar Professional
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
What analysts say about Unicycive Therapeutics Inc. stockFree Stock Chart Pattern Guide - jammulinksnews.com
What drives Unicycive Therapeutics Inc. stock priceExtraordinary earning power - jammulinksnews.com
Published on: 2025-07-18 04:29:16 - Newser
Why Unicycive Therapeutics Inc. stock is on top investor watchlistsDaily Top Gainers - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc.UNCY - PR Newswire
Why Unicycive Therapeutics Inc. stock attracts strong analyst attentionFast Moving Stock Alerts - Newser
How Unicycive Therapeutics Inc. stock performs during market volatilityReal Chart Play - Newser
What makes Unicycive Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
Transcript : Unicycive Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 11 - MarketScreener
Unicycive Regains Nasdaq Compliance After Stock Split - The Globe and Mail
Unicycive regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa
Unicycive regains Nasdaq compliance after reverse stock split - Investing.com
Unicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price Recovery - Quiver Quantitative
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Unicycive Successfully Maintains Nasdaq Listing Following 1:10 Reverse Stock Split - Stock Titan
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire
Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World
Unicycive Therapeutics to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference - Nasdaq
Clinical-Stage Kidney Disease Biotech Unicycive Reveals Latest Therapeutic Progress at Major Healthcare Conference - Stock Titan
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Unicycive Therapeutics - The Pharma Letter
Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN
Ongoing Unicycive Therapeutics, Inc. (UNCY) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Ongoing Securities Investigation Into Unicycive Therapeutics, Inc. (UNCY)Contact Levi & Korsinsky - ACCESS Newswire
Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com India
Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - FinancialContent
H.C. Wainwright keeps Buy on Unicycive Therapeutics , says CRL ‘anticipated’ - TipRanks
Unicycive stock falls after FDA issues Complete Response Letter By Investing.com - Investing.com Nigeria
Unicycive stock falls after FDA issues Complete Response Letter - Investing.com Australia
Pre-market Movers: BBLG, INMB, NAOV, AEMD... - RTTNews
Does Unicycive Therapeutics Inc (NASDAQ: UNCY) Still Need To Convince Analysts? - Stocksregister
Unicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down – What’s Next? - Defense World
Unicycive Therapeutics to execute 1-for-10 reverse stock split - MSN
Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing By Investing.com - Investing.com South Africa
Unicycive Therapeutics to Implement 1-for-10 Reverse Stock Split - MarketScreener
Unicycive Therapeutics (UNCY) Announces 1-for-10 Reverse Stock S - GuruFocus
Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing - Investing.com
Unicycive Therapeutics Announces Reverse Stock Split - marketscreener.com
Unicycive Therapeutics Inc (UNCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.17%
자본화:
|
볼륨(24시간):